Related Experiment Video
Updated: Jun 25, 2026
Rapid Diagnosis of Avian Influenza Virus in Wild Birds: Use of a Portable rRT-PCR and Freeze-dried Reagents in the Field
Published on: August 2, 2011
Evaluation of the rapid influenza detection tests GOLD SIGN FLU and Quick Navi-Flu for the detection of influenza A
Yu Akaishi1, Tetsuya Matsumoto2, Yoshimi Harada1
1Department of Primary Care and General Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
This study compared two rapid diagnostic tests for influenza A and B in adults. Researchers evaluated how accurately these tests identified viral antigens compared to standard laboratory isolation methods. Both tests provided quick results, though one showed slightly higher performance metrics than the other. These findings help clinicians understand the reliability of different point-of-care tools during flu season.
Area of Science:
- Diagnostic accuracy research within Rapid Influenza Detection Tests (RIDT) clinical medicine
- Infectious disease epidemiology and virology
Background:
Limited data exist regarding the comparative performance of newer diagnostic tools for seasonal respiratory infections. Clinicians frequently rely on point-of-care assays to guide patient management during peak viral activity. However, significant variability in diagnostic sensitivity often complicates the selection of appropriate screening platforms. Prior research has shown that existing methods frequently struggle with suboptimal detection rates for specific viral strains. That uncertainty drove the need for rigorous validation of emerging commercial kits. No prior work had resolved the performance differences between these specific diagnostic products in adult populations. This gap motivated a structured assessment of their clinical utility. Establishing clear performance benchmarks remains a priority for improving public health responses.
Purpose Of The Study:
This study aimed to evaluate the diagnostic accuracy of two specific rapid influenza detection tests in symptomatic adults. Researchers sought to compare the performance of a new kit against an established commercial product. The investigation focused on detecting viral antigens for both influenza A and B strains. By using viral isolation as a gold standard, the team intended to quantify the sensitivity and specificity of these tools. This assessment was motivated by the need to understand how different point-of-care assays perform during active flu seasons. The authors addressed the variability in diagnostic reliability that often challenges clinical decision-making. They also examined the speed at which these tests provide actionable results for healthcare providers. Ultimately, the project provides essential data to help clinicians select the most effective screening methods for their patients.
Main Methods:
The investigation employed a comparative clinical design to assess two distinct diagnostic platforms. Researchers enrolled 123 adult subjects presenting with symptoms consistent with seasonal influenza infections. Staff collected nasopharyngeal swab specimens from each participant between December 2013 and March 2014. The team utilized viral isolation as the reference standard to confirm the presence of influenza A or B. Investigators processed all samples according to manufacturer instructions for both the new and established kits. They recorded the time required for positive results to manifest on the test strips. Statistical analysis involved calculating sensitivity and specificity for each diagnostic product against the isolation results. This systematic approach ensured a robust evaluation of antigen detection capabilities across the study cohort.
Main Results:
Quick Navi-Flu exhibited superior diagnostic performance compared to the GOLD SIGN FLU platform across all measured parameters. For influenza A, GOLD SIGN FLU achieved 73.7% sensitivity and 97.6% specificity. In contrast, Quick Navi-Flu reached 86.8% sensitivity and 98.8% specificity for the same viral strain. Regarding influenza B, GOLD SIGN FLU demonstrated 81.0% sensitivity and 98.0% specificity. Quick Navi-Flu showed 85.7% sensitivity and 100% specificity for influenza B. Both assays consistently produced results in under three minutes for influenza A. For influenza B, the time to detection was less than two minutes in over 90% of instances. These findings confirm that both tools provide rapid results, though accuracy levels differ significantly between the two products.
Conclusions:
The authors suggest that both evaluated assays offer rapid diagnostic capabilities for identifying influenza antigens in symptomatic adults. Quick Navi-Flu demonstrated superior sensitivity and specificity metrics when compared directly to the GOLD SIGN FLU platform. These findings indicate that while both tools function effectively, performance variations exist between different commercial products. The researchers propose that clinicians consider these accuracy differences when selecting diagnostic resources for seasonal screening. Results from both assays appeared within a short timeframe, supporting their utility in busy clinical settings. The study highlights the importance of validating new diagnostic tools against established viral isolation standards. Future clinical decisions should incorporate these performance data to optimize patient care during flu outbreaks. These observations provide a clear framework for understanding the diagnostic reliability of current rapid testing options.
Frequently Asked Questions
The researchers report that Quick Navi-Flu achieved higher sensitivity and specificity for both influenza A and B compared to GOLD SIGN FLU. Specifically, Quick Navi-Flu reached up to 100% specificity for influenza B, whereas GOLD SIGN FLU reached 98.0%.
The study utilized nasopharyngeal swab specimens collected from 123 adult patients presenting with influenza-like symptoms. These samples were then analyzed using both the new GOLD SIGN FLU kit and the established Quick Navi-Flu product.
Viral isolation served as the gold standard for confirming the presence of influenza A and B. This method was necessary to establish a baseline for calculating the sensitivity and specificity of the rapid tests.
Nasopharyngeal swabs provided the primary data type for antigen detection. These specimens allowed researchers to compare the performance of the rapid kits against the results obtained through standard viral culture techniques.
The researchers measured the time required for a visible line to appear on the test strip. They observed that in over 90% of cases, both tests produced results in under three minutes for influenza A and two minutes for influenza B.
The authors state that Quick Navi-Flu provides better diagnostic accuracy than the alternative test. They propose that these performance metrics are relevant for clinicians choosing between different point-of-care options for adult patients.
